1. |
中华医学会风湿病学分会. 大动脉炎诊断及治疗指南. 中华风湿病学杂志, 2011, 15(2): 119-120.
|
2. |
Diao Y, Yan S, Premaratne S, et al. Surgery and endovascular management in patients with Takayasu’s arteritis: a ten-year retrospective study. Ann Vasc Surg, 2020, 63: 34-44.
|
3. |
陈作观, 刁永鹏, 刘静思, 等. 大动脉炎外科分型研究进展. 中华医学杂志, 2016, 96(28): 2277-2280.
|
4. |
刁永鹏, 陈跃鑫, 闫盛, 等. 大动脉炎116例外科手术及腔内治疗效果及安全性分析. 中华医学杂志, 2016, 96(6): 447-450.
|
5. |
Kishimoto T, Ishizaka K. Regulation of antibody response in vitro. Ⅶ. Enhancing soluble factors for IgG and IgE antibody response. J Immunol, 1973, 111(4): 1194-205.
|
6. |
Hirano T, Yasukawa K, Harada H, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature, 1986, 324(6092): 73-76.
|
7. |
Papadaki G, Goutakoli P, Tiniakou I, et al. IL-6 signaling attenuates TNF-α production by plasmacytoid dendritic cells in rheumatoid arthritis. J Immunol, 2022, 209(10): 1906-1917.
|
8. |
Lv J, Han M, Xiang Z, et al. Chlorzoxazone alleviates experimental autoimmune encephalomyelitis via inhibiting IL-6 secretion of dendritic cells. J Immunol, 2022, 208(7): 1545-1553.
|
9. |
Kamtchum-Tatuene J, Saba L, Heldner MR, et al. Interleukin-6 predicts carotid plaque severity, vulnerability, and progression. Circ Res, 2022, 131(2): e22-e33. doi: 10.1161/CIRCRESAHA.122.320877.
|
10. |
Nishihara M, Aoki H, Ohno S, et al. The role of IL-6 in pathogenesis of abdominal aortic aneurysm in mice. PLoS One, 2017, 12(10): e0185923. doi: 10.1371/journal.pone.0185923.
|
11. |
Jeremić V, Alempijević T, Mijatović S, et al. Clinical relevance of IL-6 gene polymorphism in severely injured patients. Bosn J Basic Med Sci, 2014, 14(2): 110-117.
|
12. |
Jabłońska A, Zagrapan B, Neumayer C, et al. Polymorphisms in the IL-6 and TNF-α gene are associated with an increased risk of abdominal aortic aneurysm. Int J Cardiol, 2021, 329: 192-197.
|
13. |
Danda D, Goel R, Danda S, et al. Interleukin-17F and interleukin-6 gene polymorphisms in Asian Indian patients with Takayasu arteritis. Hum Immunol, 2017, 78(7-8): 515-520.
|
14. |
Gao Q, Lv N, Dang A, et al. Association of interleukin-6 and interleukin-10 expression, gene polymorphisms, and Takayasu arteritis in a Chinese Han population. Clin Rheumatol, 2019, 38(1): 143-148.
|
15. |
Renauer PA, Saruhan-Direskeneli G, Coit P, et al. Identification of susceptibility loci in IL6, RPS9/LILRB3, and an intergenic locus on chromosome 21q22 in Takayasu arteritis in a genome-wide association study. Arthritis Rheumatol, 2015, 67(5): 1361-1368.
|
16. |
Ortiz-Fernández L, Saruhan-Direskeneli G, Alibaz-Oner F, et al. Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. Am J Hum Genet, 2021, 108(1): 84-99.
|
17. |
Kong X, Sawalha AH. Takayasu arteritis risk locus in IL6 represses the anti-inflammatory gene GPNMB through chromatin looping and recruiting MEF2-HDAC complex. Ann Rheum Dis, 2019, 78(10): 1388-1397.
|
18. |
Terao C, Yoshifuji H, Matsumura T, et al. Genetic determinants and an epistasis of LILRA3 and HLA-B*52 in Takayasu arteritis. Proc Natl Acad Sci U S A, 2018, 115(51): 13045-13050.
|
19. |
Goel R, Kabeerdoss J, Ram B, et al. Serum cytokine profile in Asian Indian patients with Takayasu arteritis and its association with disease activity. Open Rheumatol J, 2017, 11: 23-29.
|
20. |
Pathadan AP, Tyagi S, Gupta MD, et al. The study of novel inflammatory markers in Takayasu arteritis and its correlation with disease activity. Indian Heart J, 2021, 73(5): 640-643.
|
21. |
Sun Y, Kong X, Cui X, et al. The value of interleukin-6 in predicting disease relapse for Takayasu arteritis during 2-year follow-up. Clin Rheumatol, 2020, 39(11): 3417-3425.
|
22. |
Noris M, Daina E, Gamba S, et al. Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation, 1999, 100(1): 55-60.
|
23. |
Alibaz-Oner F, Yentür SP, Saruhan-Direskeneli G, et al. Serum cytokine profiles in Takayasu’s arteritis: search for biomarkers. Clin Exp Rheumatol. 2015, 33(2 Suppl 89): S-32-5.
|
24. |
Tamura N, Maejima Y, Tezuka D, et al. Profiles of serum cytokine levels in Takayasu arteritis patients: potential utility as biomarkers for monitoring disease activity. J Cardiol, 2017, 70(3): 278-285.
|
25. |
Gao Q, Wu ZY , Yu J, et al. Single-cell RNA sequencing revealed CD14+ monocytes increased in patients with Takayasu’s arteritis requiring surgical management. Front Cell Dev Biol, 2021, 9: 761300. doi: 10.3389/fcell.2021.761300.
|
26. |
Li J, Wang Y, Wang Y, et al. Association between acute phase reactants, interleukin-6, tumor necrosis factor-α, and disease activity in Takayasu’s arteritis patients. Arthritis Res Ther, 2020, 22(1): 285. doi: 10.1186/s13075-020-02365-y.
|
27. |
Maciejewski-Duval A, Comarmond C, Leroyer A, et al. mTOR pathway activation in large vessel vasculitis. J Autoimmun, 2018, 94: 99-109.
|
28. |
Rathore U, Thakare DR, Patro P, et al. A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis. Clin Rheumatol, 2022, 41(1): 33-44.
|
29. |
Kong X, Wu S, Dai X, et al. A comprehensive profile of chemokines in the peripheral blood and vascular tissue of patients with Takayasu arteritis. Arthritis Res Ther, 2022, 24(1): 49. doi: 10.1186/s13075-022-02740-x.
|
30. |
Kong X, Sun Y, Ma L, et al. The critical role of IL-6 in the pathogenesis of Takayasu arteritis. Clin Exp Rheumatol. 2016, 34(3 Suppl 97): S21-S27.
|
31. |
Kong X, Ma L, Ji Z, et al. Pro-fibrotic effect of IL-6 via aortic adventitial fibroblasts indicates IL-6 as a treatment target in Takayasu arteritis. Clin Exp Rheumatol. 2018, 36(1): 62-72.
|
32. |
Chen R, Sun Y, Cui X, et al. Autophagy promotes aortic adventitial fibrosis via the IL-6/Jak1 signaling pathway in Takayasu’s arteritis. J Autoimmun, 2019, 99: 39-47.
|
33. |
高擎, 吴志远, 李海洋, 等. 单细胞转录组测序在多发性大动脉炎肾动脉病变中的初步探索. 中国医学科学院学报, 2023, 45(1): 80-87.
|
34. |
Nishimoto N, Nakahara H, Yoshio-Hoshino N, et al. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum, 2008, 58(4): 1197-1200.
|
35. |
Nakaoka Y, Isobe M, Takei S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis, 2018, 77(3): 348-354.
|
36. |
Harigai M, Miyamae T, Hashimoto H, et al. A multicentre, large-scale, observational study of tocilizumab in patients with Takayasu arteritis in Japan: The ACT-Bridge Study. Mod Rheumatol, 2022, roac099. doi: 10.1093/mr/roac099.
|
37. |
Mekinian A, Saadoun D, Vicaut E, et al. Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial. Arthritis Res Ther, 2020, 22(1): 218. doi: 10.1186/s13075-020-02311-y.
|